Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid

Streptococcus pneumoniae polysaccharide conjugated to Corynebacterium diphtheriae toxoid is a vaccine component using inactivated diphtheria toxin as a carrier protein for pneumococcal capsular polysaccharides to elicit T-cell-dependent humoral immunity against pneumococcal serotypes. Conjugation to the protein carrier converts polysaccharides from T-independent to T-dependent antigens, enabling primary immune responses in infants and immunological memory upon re-exposure. It is incorporated in pneumococcal conjugate vaccines targeting multiple serotypes.

Yes, Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.